Multiple-delayed release formulation approach for the treatment of methicillin-resistant Staphylococcus aureus

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most frequent nosocomial pathogens in developed countries. Although several novel antibacterial agents possessing novel mode of action have been developed to date, the continuous effort to investigate an effective combination of front-line drugs is considered important in anti-MRSA drug development. The combination chemotherapy with front-line drugs is expected to provide effective, safe, and less expensive treatment. Oral trimethoprim/sulfamethoxazole combination therapy has been utilized for treatment of several nosocomical infections. Importantly, no antagonism has been reported for combinations of trimethoprim with many other front-line antibiotics. MiddleBrook Pharmaceuticals has developed the pulsatile delivery systems of three to four different antibacterial agents, including trimethoprim and sulfamethoxazole, for the treatment of MRSA infections. The liberation of individual drugs theoretically follows a programmable lag phase (no release) from the time of administration. Pulsatile drug delivery system provides optimal release profiles for a combination of drugs. The clinical data that would be obtained based on these claims are expected to be of significance in terms of developing combination chemotherapy for MRSA infections via a pulsatile drug release control system.

Keywords::

• combination therapy
• dihydrofolate reductase inhibitor
• dihydropteroate synthase inhibitor
• LexA protease cleavage inhibitor
• methicillin-resistant Staphylococcus aureus (MRSA)
• phenazine antibiotic
• RNA-polymerase inhibitor
• time-controlled pulsatile delivery system

Notes